Effect of Repaglinide Combined with Insulin Degludec in the Treatment of Obese Type 2 Diabetes Mellitus and Its Effect on Lipid Metabolism and In-sulin Resistance
Objective To analyze the combined effect of repaglinide and insulin degludec in the clinical treatment of obese patients with type 2 diabetes mellitus(T2DM).Methods A total of 80 obese T2DM patients admitted to Ninghua County General Hospital from June 2021 to June 2024 were selected as the research objects and divided into two groups according to different treatment methods.The control group(34 cases)was treated with insulin degludec,and the study group(46 cases)was treated with repaglinide on the basis of the control group.The clinical efficacy,levels of glucose and lipid metabolism,islet function and adverse reactions were compared between the two groups.Results The total effective rate of treatment in the study group was higher than that in the control group,the difference was statisti-cally significant(P<0.05).After treatment,the levels of fasting insulin,islet β-cell function index and high-density li-poprotein in the study group were higher than those in the control group,and the levels of fasting blood glucose,2-hour postprandial blood glucose,glycated hemoglobin A1c,insulin resistance index,low-density lipoprotein,triglyceride and total cholesterol were lower than those in the control group,the differences were statistically significant(all P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion In the clinical treatment of obese T2DM,the combined application of repaglinide and insulin degludec can effectively control the blood glucose index of patients,regulate the body's glucose and lipid metabolism,enhance islet function,and reduce insulin resistance,and the treatment is safe and practical.
RepaglinideInsulin degludecObese type 2 diabetes mellitusIslet functionGlucose and lipid metabolism
维普
万方数据
